Immutep Limited (IMMP) Stock Analysis
A live, multi-source view of Immutep Limited (IMMP): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Immutep Limited
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma.
Sector: Healthcare · Industry: Biotechnology · Australia · immutep.com
Key statistics · as of 2026-09-09
As of 2026-09-09, Immutep Limited (IMMP) had a market capitalization of $53.8M (forward -1.8) and a beta of 2.20; the shares traded in a 52-week range of $0.29 – $3.53 (-77.5% over the year).
- Market cap
- $53.8M
- Enterprise value
- $-14.1M
- Forward P/E
- -1.8
- Price / book
- 1.21
- EPS (trailing)
- $-0.39
- EPS (forward)
- $-0.20
- Payout ratio
- 0.0%
- 52-week range
- $0.29 – $3.53
- 52-week change
- -77.5%
- Beta
- 2.20
- Average volume
- 255,943
- Shares outstanding
- 147.4M
- Short % of float
- 0.53%
- Profit margin
- 0.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-10
In RapidTradeView’s 2026-09-10 scan of the US universe, Immutep Limited (IMMP) last closed at $0.36 (the last completed close before that scan).
Technicals at the scan: RSI 37 (neutral territory), price -5.3% versus its 20-day average, 20-day versus 50-day average spread -5.0%, MACD histogram -0.00.
Sentiment inputs: StockTwits 35% bullish.
Next scheduled company event: in 166 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
RapidTradeView has recorded no Congress or insider filing for IMMP in the last 90 days. Coverage of House, Senate and SEC Form 4 filings began in July 2026, and insider sells are tracked for universe tickers only, so this is our record, not a guarantee that nothing was filed. Who is trading what
RapidTradeView pick record
IMMP has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Immutep Limited (IMMP) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell IMMP.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.